Editorials

Adjuvant treatment for colorectal cancer

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7028.392 (Published 17 February 1996) Cite this as: BMJ 1996;312:392
  1. Maurice L Slevin
  1. Consultant physician and medical oncologist St Bartholomew's Hospital, London EC1A 7BE

    No more room for nihilism

    It is now over five years since the publication of two randomised trials showing that fluorouracil and levamisole reduced the relapse rate by 40% and mortality by a third in patients with node positive colorectal cancer.1 2 The final report of these data was recently published, showing 168 deaths in control patients versus only 121 in patients who received adjuvant treatment (P<0.005).3 Despite these data, a recent survey of oncologists and surgeons in Britain showed that most oncologists offered adjuvant chemotherapy to appropriate patients while many surgeons remained sceptical (R Grey, personal communication).

    The combination of fluorouracil and folinic acid has proved superior to fluorouracil alone in patients with advanced colorectal cancer.4 The Canadian and Eurpean consortium trial (IMPACT) compared adjuvant treatment with high dose fluorouracil and folinic acid with no treatment in nearly 1500 patients; it showed a 22% reduction in mortality, predominantly in patients with Dukes's type C colon cancer.5 A similar but much smaller Italian study showed a 39% …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe